Appendix 3: Data extraction form

General
• First author, year
• Date of extraction and assessment
• Origin of study (all countries)
• Publication year
• Funding from pharmaceutical industry (fully, partly, or no funding from pharmaceutical industry, unknown)

Study population
• Disease/condition
• Age groups (mean)
• Gender distribution
• Ethnicity distribution
• In-/outpatient
• Sample size

Aspects of the preference elicitation
• Objective of the overall study (Main, secondary/supporting, other)
• Medication(s) involved
• Purpose of the preference elicitation (Economic assessment in public policy/ economic assessment in pharmaceutical industry, benefit to individual patients, research prioritisation, other)
• Sources used in attribute, health state or option selection and construction (researcher, research, clinician, patient, other)
• Preference elicitation method(s)
• Categories presented for preference elicitation (treatment options/treatment attributes/health states/health domains/other)

Results
• Main conclusions of the study
• Outcomes included in the study
• Preference rankings
• Relative strengths of preferences
• Heterogeneity of patients’ preferences. If sub-group analysis was performed: results for each subgroup
• Comparative results for different stakeholder group preference weightings
• Feasibility measures, results, and conclusions
• Correlations between patient preferences and demographic/disease variables: results
• Other main findings as reported by authors